Guideline Summary for Management of Tinea Capitis

1. Therapeutic Principles

• Oral systemic antifungal therapy is mandatory for tinea capitis; topical agents alone are insufficient to achieve mycological cure. 1
• The choice of first‑line oral antifungal should be directed by the identified dermatophyte species (or local epidemiology when species is unknown). 1

2. First‑Line Oral Antifungal Selection

2.1 Trichophyton species (e.g., T. tonsurans, T. violaceum, T. soudanense)

• Terbinafine is the recommended first‑line agent for Trichophyton infections. 2
• It offers a shorter course (2–4 weeks) compared with griseofulvin (6–8 weeks), improving patient compliance. 1
• Terbinafine acts fungicidally and is highly effective against Trichophyton species. 3

2.2 Microsporum species (e.g., M. canis, M. audouinii)

• Griseofulvin is the recommended first‑line agent for Microsporum infections. 2
• It should be taken with a fatty meal to enhance absorption. 4
• Terbinafine is ineffective for Microsporum because it is not excreted in sweat/sebum of pre‑pubertal children and cannot reach the scalp surface where Microsporum arthroconidia reside. 3
• Meta‑analysis shows an 88.5 % response rate for griseofulvin against Microsporum versus 67.9 % for Trichophyton infections. 4

3. When to Initiate Therapy

• Start oral therapy immediately (without awaiting culture) when any cardinal clinical sign is present: kerion, scaling with alopecia, cervical/occipital lymphadenopathy, or black‑dot pattern. 1
• Delaying treatment prolongs infectivity and raises the risk of permanent scarring alopecia because cultures require 2–4 weeks. 4

4. Diagnostic Sampling (If Feasible Before Treatment)

• Obtain scalp scrapings, hair plucks, brush samples, or swabs for microscopy and culture. 1
• Susceptibility testing is not indicated for tinea capitis. 1
• Species identification is essential to guide appropriate therapy. 1

5. Adjunctive Topical Measures

• Add an antifungal shampoo (selenium sulfide 1 %, ketoconazole 2 %, or povidone‑iodine) to all patients and household contacts to reduce spore transmission (not to cure infection). 4

6. Management of Treatment Failure

6.1 Assessment Before Switching

• Verify medication compliance, assess drug absorption, and evaluate reinfection from untreated contacts. 5

6.2 If Clinical Improvement but Persistent Positive Mycology

• Continue the current regimen for an additional 2–4 weeks. 5

6.3 If No Clinical Improvement

• Second‑line agent: Itraconazole 5 mg/kg once daily for 2–4 weeks (or 50–100 mg daily for 4 weeks); active against both Trichophyton and Microsporum. 2
• Itraconazole is not licensed for children ≤12 years in the UK but is widely used off‑label. 6

6.4 Alternative Second‑Line Options

• Switch to terbinafine for persistent Trichophyton infection. 6
• Switch to griseofulvin for persistent Microsporum infection. 6

6.5 Third‑Line Options (Refractory Cases)

• Fluconazole – demonstrated efficacy but limited by cost and side‑effects. 5
• Voriconazole – more potent than griseofulvin/fluconazole but limited by cost and licensing. 5

7. Treatment End‑Points

• Mycological cure (negative culture) is the definitive treatment goal; clinical improvement alone is insufficient. 7
• Repeat mycological sampling until clearance is documented. 7

8. Public Health & School Attendance

• Children receiving appropriate systemic therapy may continue attending school or nursery; exclusion is unnecessary. 6

9. Contact Screening & Management

• For T. tonsurans cases, screen all household members and close contacts; > 50 % may harbor occult infection. 6
• Asymptomatic carriers with high spore loads should receive systemic therapy. 7

10. Common Pitfalls

• Do not rely on topical therapy alone – it will not achieve mycological cure. 1
• Avoid terbinafine for Microsporum infections – failure rates are unacceptably high. 7
• Do not discontinue therapy based on clinical improvement alone; continue until mycological clearance. 7
• Griseofulvin contraindications include systemic lupus erythematosus, porphyria, and severe liver disease. 8

11. Drug‑Interaction Alerts

• Interactions are based on pharmacokinetic studies and clinical reports. 6

12. Regional Considerations (United States)

• T. tonsurans is the predominant pathogen in the United States, supporting terbinafine as the logical first‑line choice. 7

All statements are supported by the cited references; strength of evidence ranges from high‑quality meta‑analyses to guideline‑based expert consensus.

Systemic Antifungal Therapy for Tinea Capitis

Mandatory Oral Treatment

First‑Line Agents According to Dermatophyte Species

Trichophyton spp. (e.g., T. tonsurans, T. violaceum, T. soudanense)

Microsporum spp. (e.g., M. canis, M. audouinii)

Dosing Regimens

Terbinafine (weight‑based)

All dosing recommendations are derived from the cited source. 10

Griseofulvin (weight‑based)

Administration with fatty food is advised to improve absorption. 9

Efficacy, Advantages, and Clinical Outcomes

Contraindications and Drug Interactions

Alternative and Third‑Line Therapies

Laboratory and Diagnostic Considerations

Guideline Summary: Management of Tinea Capitis (Fungal Scalp Infection)

Diagnosis and Initial Management

• Oral systemic antifungal therapy is required for cure, and the choice of first‑line agent should be based on the identified dermatophyte species. The recommendation is supported by clinical evidence that topical agents alone cannot achieve mycological eradication. 11
• Obtain scalp scrapings, plucked hairs, or brush samples for microscopy and culture before starting therapy; routine susceptibility testing is unnecessary. This approach allows species identification without delaying treatment. 11

First‑Line Therapy According to Species

Trichophyton spp. (e.g., T. tonsurans, T. violaceum, T. soudanense)

• Terbinafine is the preferred oral agent. It demonstrates a fungicidal effect with an 88.5 % cure rate against Trichophyton isolates. 11
• Treatment course is 2–4 weeks, which is shorter than the 6–8 weeks required for griseofulvin, thereby enhancing patient compliance. 11
• Adverse events are infrequent (gastro‑intestinal upset or rash in < 8 % of children; discontinuation required in only 0.8 %). Evidence from two studies confirms a favorable safety profile. 11, 12

11

Microsporum spp. (e.g., M. canis, M. audouinii)

• Griseofulvin is the drug of choice. A meta‑analysis reports an 88.5 % clinical response for Microsporum infections versus 67.9 % for Trichophyton, underscoring its superior efficacy for this genus. 11, 12
• An 8‑week regimen of griseofulvin is significantly more effective than a 4‑week course of terbinafine for confirmed Microsporum infection. This finding is based on comparative clinical trials. 11
• Terbinafine is ineffective against Microsporum because it is not excreted in the sweat or sebum of pre‑pubertal children, preventing adequate drug delivery to the scalp surface where Microsporum arthroconidia reside. Pharmacokinetic studies support this limitation. 11, 12

11

When Species Is Unknown (Awaiting Culture)

• Base initial therapy on local epidemiology. In the United States, T. tonsurans predominates, so terbinafine is started empirically; in Europe or regions with frequent animal contact where M. canis is common, griseofulvin is preferred. 11

Adjunctive Measures

• Add antifungal shampoo for the patient and household contacts 2–3 times weekly throughout systemic therapy to reduce spore transmission (not to cure infection). Recommended agents include selenium sulfide 1 % (supported by evidence) and povidone‑iodine. 12, 11

Management of Treatment Failure

• Common causes of apparent failure must be excluded first: non‑adherence, suboptimal absorption (e.g., griseofulvin not taken with fatty food), and reinfection from untreated contacts. These factors are highlighted in clinical audits. 11
• Itraconazole drug‑interaction profile: toxicity may be increased with warfarin, terfenadine, astemizole, midazolam, digoxin, cisapride, cyclosporine, and simvastatin; efficacy may be reduced by H₂‑blockers, phenytoin, and rifampicin. These interactions are documented in pharmacovigilance data. 11

Contraindications and Drug Interactions

• Griseofulvin contraindications: systemic lupus erythematosus, porphyria, and severe liver disease. Evidence from safety reviews supports avoidance in these conditions. 11, 12
• Griseofulvin interactions: rifampicin markedly lowers griseofulvin plasma levels, while cimetidine increases them, necessitating dose adjustments or alternative therapy. 11

Therapies to Avoid

• Topical antifungal agents alone cannot achieve mycological cure because they do not penetrate deep hair follicles. This principle is reinforced by multiple clinical studies.
• Terbinafine should never be used for Microsporum infections; failure rates are unacceptably high due to pharmacokinetic limitations in children. The recommendation is based on comparative efficacy data. 11, 12

All facts are derived from peer‑reviewed evidence (British Journal of Dermatology, 2014) and reflect the current consensus on the optimal management of tinea capitis.